Clermont-Ferrand, France – July 21, 2026 — Sepul Bio, an innovative business unit of Laboratories Théa dedicated to advancing therapies for inherited retinal diseases, today announced the enrollment of the final participant in the Phase 2b LUNA clinical trial of Ultevursen in patients with Usher syndrome type 2A (USH2A)-associated retinitis pigmentosa (RP) or non-syndromic RP.
“Achieving the enrollment of the final participant in the Phase 2b LUNA clinical trial represents a fantastic milestone for USH2A research,” said Dr. Robert Koenekoop, MD, PhD, Professor in the Department of Pediatric Surgery at the Faculty of Medicine and Health Sciences, McGill University.
“This moment takes us one step closer in our search for therapies for this condition of high unmet need. The LUNA clinical trial, being conducted across 26 active clinical sites in 10 countries, is exploring the impact of RNA therapies on individuals with USH2A-associated RP due to variants in exon 13 of the USH2A gene.”
“We are thrilled to see the full enrollment of the LUNA clinical trial,” said Krista Vasi, MPA, Executive Director of the Usher Syndrome Coalition.
You can read the full press release here: https://thea.com/en_WW/news/sepul-bio-completes-luna-phase-2b-trial-enrollment-for-ultevursen